AI is reshaping the doctor visit—just not how you think

AI healthcare deals are roaring. 

Digital health startups raised $14.2 billion in 2025, up 35% from 2024, with AI‑enabled companies capturing 54% of that capital and enjoying roughly a 19% premium on average deal size versus non‑AI peers, research from Rock Health details. Investors have rushed into ambient scribes, agentic triage tools, and “doctor‑copilot” platforms—including Abridge (an AI-powered clinical scribe) which raised about $550 million across two mega‑rounds in 2025.

But Zocdoc CEO Oliver Kharraz is spending his time asking a less glamorous question: What actually happens when patients show up in the exam room armed with AI answers? 

Zocdoc—backed by Francisco Partners, Atomico, Baillie Gifford, DST Global, and Goldman Sachs—was valued at roughly $1.8 billion in 2015 after a $130 million round led by Baillie Gifford and Atomico, making it one of New York’s highest‑valued private tech companies at the time. In 2021, Zocdoc raised $150 million in growth financing from Francisco Partners after growing revenue more than 35% year over year pre‑pandemic.

Now pitching itself as “healthcare access infrastructure,” Zocdoc says millions of patients each month use its marketplace to find in‑network doctors. 

The company’s latest........

© Fortune